SCN9A and erythromelalgia: We used the iPSC line RCi002-A, which is derived from a patient with inherited erythromelalgia (IEM) and carries the F1449V gain-of-function mutation in Nav1.7, and has previously been demonstrated to exhibit spontaneous firing when differentiated into nociceptors (Cao et al., 2016).